Dialybrid is a clinical-stage medical device company that provides vascular grafts for hemodialysis using silk fibroin and polyurethane.
Dialybrid has raised $17.2M in total funding. The most recent round was Series A. The last funding was announced in September 2026.
Dialybrid's investors include CDP Venture Capital, XGEN Venture, LIFTT.
Dialybrid is headquartered in Cantu, Italy.
Dialybrid is a clinical-stage medical device company that provides vascular grafts for hemodialysis using silk fibroin and polyurethane.
Dialybrid is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Dialybrid — Funding & Investors." VCBacked, September 22, 2026, https://www.vcbacked.co/company/dialybrid. Accessed November 13, 2026.
VCBacked. (2026). Dialybrid — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/dialybrid
{{cite web |title=Dialybrid — Funding & Investors |url=https://www.vcbacked.co/company/dialybrid |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Dialybrid? Request a listing update